Loading organizations...
LightDeck Diagnostics is a technology company.
LightDeck Diagnostics develops rapid, point-of-care diagnostic solutions leveraging advanced planar waveguide technology. This proprietary platform integrates laser-activated fluorescence and microfluidics into disposable test cartridges and a portable analyzer. The system delivers lab-quality results swiftly, finding applications in human health, veterinary medicine, and environmental monitoring.
The company originated in 2009 as MBio Diagnostics, founded by Christopher J. Myatt. Originating from insights by optical measurement scientists in Nobel-prize winning laboratories, its initial focus was a waveguide platform. In July 2020, MBio Diagnostics merged with Brava Diagnostics, rebranding as LightDeck Diagnostics, reflecting dedication to this core technology.
LightDeck Diagnostics serves healthcare providers, veterinarians, and environmental technicians with accessible diagnostics across diverse settings. The company's vision focuses on enabling decentralized, lab-quality testing to empower timely decision-making. It aims to provide fast, accurate, and dependable results for patient care and crucial environmental monitoring.
LightDeck Diagnostics has raised $36.1M across 5 funding rounds.
LightDeck Diagnostics has raised $36.1M in total across 5 funding rounds.
LightDeck Diagnostics has raised $36.1M in total across 5 funding rounds.
LightDeck Diagnostics's investors include Boulder Ventures, Entrada Ventures, Michael Chang, Heska Corporation, Techstars.
# LightDeck Diagnostics: Point-of-Care Diagnostic Innovation
LightDeck Diagnostics is a medical device company that develops rapid, portable diagnostic testing platforms delivering lab-quality results in minutes.[2][3] Founded in 2009 and headquartered in Boulder, Colorado, the company specializes in point-of-care diagnostics using proprietary planar waveguide fluorescence technology.[1][4] LightDeck serves healthcare, veterinary, and environmental testing sectors, addressing the fundamental problem that accurate diagnostic testing has traditionally required centralized laboratory infrastructure—slow, expensive, and geographically limiting.[3][4]
The company's core mission centers on democratizing diagnostics: enabling "fast, accurate, simple, low-cost diagnostic tests to be run wherever and whenever they are needed, without compromise."[3][4] LightDeck achieved significant commercial traction in veterinary diagnostics and environmental testing before being acquired by Heska Corporation (NASDAQ: HSKA) in January 2023.[2] The acquisition reflected recognition of LightDeck's manufacturing capabilities, intellectual property portfolio, and potential to scale across multiple diagnostic applications.
LightDeck was established in 2009 in Boulder, Colorado, emerging from deep technical expertise in assay development, microfluidics, and manufacturing.[4] The company built an 80-member team of "industry veterans, engineers, and scientists" who collaborated with commercial, academic, and government partners to develop an extensive intellectual property portfolio.[4] By the time of acquisition, LightDeck had secured 16 U.S. patents and 15 international patents with applications spanning veterinary diagnostics, water testing, and human in-vitro diagnostics.[4]
A pivotal moment came in 2022 when LightDeck was named to *Fast Company*'s World's Most Innovative Companies list, validating its technological approach and market potential.[2] The company had also secured significant government funding, including a $2 million grant from the Henry M. Jackson Foundation for the Advancement of Military Medicine to develop rapid, multiplexed inflammation tests.[5] These milestones demonstrated both technical credibility and commercial viability before the Heska acquisition.
LightDeck operates at the intersection of two powerful trends: decentralization of healthcare diagnostics and miniaturization of laboratory technology. The company addresses a critical market gap—the global demand for rapid, accurate testing outside traditional laboratory settings has accelerated dramatically, particularly post-pandemic.
The timing proved strategic. Point-of-care diagnostics represent a multi-billion-dollar market opportunity as healthcare systems seek to reduce turnaround times, lower costs, and improve patient outcomes through faster decision-making. LightDeck's acquisition by Heska, a publicly traded veterinary diagnostics leader, signals institutional validation that planar waveguide technology can compete with established diagnostic platforms and scale profitably.
The company's influence extends beyond its direct products: by demonstrating that sophisticated fluorescence-based diagnostics can be miniaturized and automated, LightDeck influences broader industry expectations around what point-of-care testing can achieve in terms of accuracy and complexity.
LightDeck's integration into Heska positions the technology for significant scale. Heska's stated objective—to "drive gross margin improvement with new manufacturing capabilities and scaling across the business"—suggests the Longmont facility will enable rapid commercialization of the human diagnostics pipeline.[4] The company's intellectual property breadth (31 patents) and manufacturing expertise create defensible competitive advantages in an increasingly crowded point-of-care diagnostics market.
The critical question ahead is execution: can Heska successfully transition LightDeck's technology from veterinary and environmental applications into human clinical diagnostics at scale? Success would validate planar waveguide technology as a platform capable of competing with established players like Abbott and Roche in the high-volume diagnostics market. The company's trajectory suggests LightDeck will remain a significant player in the shift toward distributed, rapid diagnostic testing—a trend unlikely to reverse.
LightDeck Diagnostics has raised $36.1M across 5 funding rounds. Most recently, it raised $9.9M Other Equity in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 4, 2021 | $9.9M Other Equity | ||
| Oct 29, 2020 | $11.0M Series B | Boulder Ventures, Entrada Ventures, Michael Chang | |
| Aug 1, 2018 | $5.0M Series B | Heska Corporation | Techstars |
| May 22, 2015 | $6.3M Series B | ||
| Sep 26, 2012 | $3.9M Other Equity |